Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Thompson

Showing results (11-20 of 484) with videos related to

Pageof 49
Sort By:
Drugs of Today (Barcelona, Spain : 1998)|May 24, 2003
Pharmacologic agents in complementary medicine in prostatic diseaseIan M. Thompson
European Urology|May 23, 2024
Prostate-specific Antigen Screening in Limbo: How Low Should We Go?Ian M Thompson
The Canadian Journal of Urology|February 12, 2022
Legends in Urology V29I01Ian M Thompson
Urology|February 1, 2003
Informed consent for prostate cancer screening--a call for equity in medical interventionsIan M Thompson
The Journal of Urology|January 10, 2004
Balancing cure and quality of life after radical prostatectomyIan M Thompson
Cancer|May 23, 2018
The pendulum swings back: Screening for prostate cancer in 2018Ian M Thompson
The New England Journal of Medicine|February 2, 2017
Improved Therapy for PSA Recurrence after ProstatectomyIan M Thompson
The Journal of Urology|January 16, 2026
How "Floor Bias" in Gleason Grading Affects Prostate Cancer ManagementIan M Thompson
Cancer|August 27, 2004
Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarkerJavier Hernández, Ian M Thompson
Cancer|March 3, 2005
Carcinoma core distribution in patients with palpable and nonpalpable prostate tumorsJavier Hernandez, Ian M Thompson
Pageof 49

Showing results (11-20 of 484) with videos related to

Sort By:
Pageof 49
Drugs of Today (Barcelona, Spain : 1998)|May 24, 2003
Pharmacologic agents in complementary medicine in prostatic diseaseIan M. Thompson
European Urology|May 23, 2024
Prostate-specific Antigen Screening in Limbo: How Low Should We Go?Ian M Thompson
The Canadian Journal of Urology|February 12, 2022
Legends in Urology V29I01Ian M Thompson
Urology|February 1, 2003
Informed consent for prostate cancer screening--a call for equity in medical interventionsIan M Thompson
The Journal of Urology|January 10, 2004
Balancing cure and quality of life after radical prostatectomyIan M Thompson
Cancer|May 23, 2018
The pendulum swings back: Screening for prostate cancer in 2018Ian M Thompson
The New England Journal of Medicine|February 2, 2017
Improved Therapy for PSA Recurrence after ProstatectomyIan M Thompson
The Journal of Urology|January 16, 2026
How "Floor Bias" in Gleason Grading Affects Prostate Cancer ManagementIan M Thompson
Cancer|August 27, 2004
Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarkerJavier Hernández, Ian M Thompson
Cancer|March 3, 2005
Carcinoma core distribution in patients with palpable and nonpalpable prostate tumorsJavier Hernandez, Ian M Thompson
Pageof 49